Effect of apraclonidine on blood-aqueous barrier

Annals of Ophthalmology - Glaucoma

Volumn 31, Issue 3, 1999, Pages 176-179

  Sobaci, Güngör ^a,b   Mutlu, F Mehmet ^b   Söyler, Mehmet ^b   Tatar, Tamer ^b   Yildirim, Erol ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Dept Ophthalmol Gulhane Mil M ^*

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD EYE BARRIER; CATARACT EXTRACTION; CONTROLLED STUDY; CRYOTHERAPY; DRUG EFFECT; EYE INFLAMMATION; FEMALE; GLAUCOMA; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RABBIT; TOPICAL DRUG ADMINISTRATION;

EID: 0032976507     PISSN: 10794794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hoskins HD, Kass M. Aqueous humour formation. In: Hoskins HD Jr., Kass M, eds. Diagnosis and Therapy of the Glaucomas. St Louis: Mosby; 1989:18-40.
2. Caprioli J. The ciliary epithelia and aqueous humour. In: Hart W, ed. Adler's Physiology of the Eye. St. Louis: Mosby-Year Book; 1992:228-247.
3. Krause U, Raunio V. The proteins of the pathologic human aqueous humour. Ophthalmologica. 1970;166:280-287.
4. Araie M, Ishi K. Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation. Am J Ophthalmol. 1993;116:67-71.
5. Wiles SB, MacKenzie D, Ide CH. Control of intraocular pressure with apraclonidine hydrochloride after cataract extraction. Am J Ophthalmol. 1991;111:184-188.
6. Sugiyama K, Kitazawa Y, Kawai K. Apraclonidine effects on ocular responses to YAG laser irradiation to the rabbit iris. Invest Ophthalmol Vis Sci. 1990;31(4):708-714.
7. Bonomi L, Bellucci R, Pagliarusco A, Stefani L. Apraclonidine protection of the blood-aqueous barrier from traumatic breakdown. J Ocul Pharmacol Ther. 1995;11(1):25-35.
8. Polack FM, Roetth A. Effect of freezing on the ciliary body (cyclocryotherapy). Invest Ophthalmol Vis Sci. 1964;3(2):164-170.
9. Prost M. Cyclocryotherapy for glaucoma: evaluation of techniques. Surv Ophthalmol. 1983;28(2):93-100.
10. Pedersen OO, Tonjum AM. Protein diffusion barriers in the anterior uvea of the rabbit eye. Acta Ophthalmologica. 1976;53:67-76.
11. Weinreb RN, Weaver D, Mitchell MD. Prostanoids in rabbit aqueous humour: effect of laser photocoagulation of the iris. Invest Ophthalmol Vis Sci. 1985;26:1087-1092.
12. Huang AS, Pollack IP. Apraclonidine and the treatment of glaucoma. Ophthalmol Clin North Am. 1995;8:303-314.
13. Yüksel N, Güler C, Çaólar Y, Elibol O. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol. 1992;16:337-342.
14. Mori M, Araie M. Effect of apraclonidine on blood-aqueous barrier permeability to plasma protein in man. Exp Eye Res. 1992;54: 555-559.
15. Freddo TF, Bartels SP, Barsotti MF, Kamm RD. The source of proteins in the aqueous humour of the normal rabbit. Invest Ophthalmol Vis Sci. 1990;31:125-137.
16. Raviolo G. The structural basis of the blood-aqueous barriers. Exp Eye Res. 1977;25(suppl):27-63.
17. Quigley HA. Histological and physiological studies of cyclocryotherapy in primate and human eyes. Am J Ophthalmol. 1976;82:722-732.
18. Fahrenbach WH, Bacon DR, van Buskirk EM. Microvascular responses to chronic glaucoma drug therapy. Invest Ophthalmol Vis Sci. 1991;32:944.
19. Chandler ML, DeSantis L. Studies of p-aminoclonidine as a potential anti-glaucoma agent. Invest Ophthalmol Vis Sci. 1985;26 (suppl):227.
20. Funk R, Rohen JW. Scanning electron microscopical and microendoscopical studies on the vasculature of human and rabbit ciliary processes. Invest Ophthalmol Vis Sci. 1990;31(suppl):380.
21. Fahrenbach WH, Bacon DR, Van Burkirk EM. Vasoactive drug effects on the uveal vasculature of the rabbit: a corrosive casting study. Invest Ophthalmol Vis Sci. 1989;30(suppl):100.
22. Silverstone DE, Novack GD, Kelly EP, Chen KS. Prophylactic treatment of intraocular pressure elevations after Neodymium:YAG laser posterior capsulotomies and extracapsular cataract extractions with levobunolol. Ophthalmology. 1988;95:713-718.
23. Mori M, Araie M. A simple method of determining the time course of timolol's effects on aqueous flow in humans. Arch Ophthalmol. 1991;109:1099-1103.
24. Abrams DA, Robin A, Pollack IP. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol. 1987;105:1205-1207.
25. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO2145). Ophthalmology. 1988;95:1217-1220.
26. Kaufman PL, Gabelt B. Alpha 2-adrenergic agonist effects on aqueous humour dynamics. J Glaucoma. 1995;4(suppl 1):8-14.
27. Tafoya ME, Toris CB, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Invest Ophthalmol Vis Sci. 1993;34:929.
28. McCannel C, Koskela T, Brubaker RF. Topical flurbiprofen pretreatment does not block apraclonidine's effect on aqueous flow in humans. Arch Ophthalmol. 1991;109:810-811.
29. Siegel MJ, Camras CB, Lustgarten JS, Podos SM. Effect of flurbiprofen on the reduction of intraocular pressure after administration of 1% apraclonidine in patients with glaucoma [letter]. Arch Ophthalmol. 1992;110:598-599.
30. Gross JG, Meyer DR, Robin AL, Filar AA, Kelley JS. Increased intraocular pressure in the immediate period after extracapsular cataract extraction. Am J Ophthalmol. 1988;105:466-459.